Table 1.
Characteristics of AGEN-MAP/PP studies.
| Study | N | Ancestry | Blood pressure measurement (device, number of measures) |
Age (SD)* | Women† | BMI (SD)‡ | SBP (SD)§ | DBP (SD)§ | MAP (SD)§,‖ | PP (SD)§,¶ | Hypertension†,# | Anti- hypertension medication† |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage-1: AGEN-MAP/PP GWAS meta-analysis (n=26,600) | ||||||||||||
| CAGE | 1,547 | Japanese | Standard mercury sphygmomanometer, 2–3/digital, 2–3 | 66.1 (8.0) | 42.8 | 23.5 (3.3) | 134.1 (20.3) | 76.8 (11.9) | 98.4 (14.5) | 59.2 (15.6) | 56.1 | 37.9 |
| CLHNS | 1,787 | Filipino | Standard mercury sphygmomanometer, 3 | 48.4 (6.1) | 100 | 24.3 (4.4) | 120.0 (20.5) | 79.8 (12.7) | 93.2 (14.5) | 40.2 (12.8) | 27.3 | 3.8 |
| GenSalt | 1,881 | Chinese | Random zero sphygmomanometer, 9 | 38.7 (9.5) | 47.2 | 23.3 (3.2) | 116.9 (14.2) | 73.7 (10.3) | 88.2 (10.9) | 43.2 (9.5) | 9.8 | 0.37 |
| KARE | 8,842 | Korean | Standard mercury sphygmomanometer, 3 | 52.2 (8.9) | 52.7 | 24.6 (3.1) | 118.7 (19.4) | 75.6 (12.0) | 90.0 (13.8) | 43.1 (11.8) | 22.3 | 10.9 |
| NHAPC | 2,817 | Chinese | Omron HEM-705 CP Blood Pressure Monitor, 3 | 58.6 (6.0) | 56.9 | 24.5 (3.6) | 143.0 (24.8) | 81.6 (11.7) | 102.0 (14.9) | 61.5 (18.2) | 55.9 | 28.7 |
| SiMES | 2,538 | Malay | Random zero sphygmomanometer, 2–3 | 59.1 (11.1) | 50.5 | 26.4 (5.1) | 150.2 (24.8) | 81.2 (11.4) | 104.2 (10.9) | 69.0 (19.1) | 69.9 | 23.0 |
| SP2 | 2,434 | Chinese | Random zero sphygmomanometer, 2–3 | 48.1 (11.2) | 53.5 | 22.9 (3.7) | 130.8 (21.3) | 77.6 (11.2) | 95.3 (13.6) | 53.2 (14.9) | 18.0 | 14.3 |
| Taiwan Type 2 Diabetes Study | 1,000 | Chinese | Random zero sphygmomanometer, 3 | 51.2 (17.8) | 49.8 | 23.8 (3.5) | 122.6 (19.4) | 76.5 (11.0) | 91.9 (12.7) | 46.1 (14.4) | 8.9 | 6.8 |
| Vanderbilt | 3,754 | Chinese | Sphygmomanometer, 2–3 | 57.1 (8.4) | 76.0 | 24.8 (3.5) | 128.7 (19.4) | 80.5 (10.5) | 96.5 (12.6) | 48.2 (14.4) | 49.0 | 22.7 |
| Stage-2: Replication study (n=28,783) | ||||||||||||
| In-silico genotyping studies (n=5,584) | ||||||||||||
| HEXA | 3,703 | Korean | Standard mercury sphygmomanometer, 2 | 53.2 (8.3) | 55.4 | 24.0 (2.9) | 121.7 (14.4) | 77.1 (9.9) | 91.9 (10.7) | 44.7 (9.2) | 18.7 | 0 |
| SCES | 1,881 | Chinese | Random zero sphygmomanometer, 3 | 58.4 (9.5) | 48.7 | 23.7 (3.5) | 140.8 (20.5) | 80.6 (9.9) | 100.7 (12.1) | 60.2 (16.3) | 56.1 | 51.8 |
| De-novo genotyping studies (n=23,199) | ||||||||||||
| CAGE-Amagasaki | 5,331 | Japanese | Digital, 2–3 | 47.8 (12.3) | 39.8 | 23.0 (3.2) | 124.3 (17.3) | 75.9 (11.0) | 92.1 (12.9) | 48.4 (8.5) | 57.9 | 23.9 |
| JMGP | 11,570 | Japanese | Digital cuff-oscillometric device, 2 | 56.1 (14.0) | 50.0 | 23.0 (3.1) | 131.3 (19.6) | 78.4 (11.6) | 96.0 (13.4) | 52.6 (13.1) | 41.6 | 19.2 |
| SMWHS | 3,237 | Chinese | Sphygmomanometer, 2–3 | 59.3 (8.8) | 56.0 | 25.3 (3.6) | 132.6 (19.6) | 82.6 (10.5) | 100.7 (13.4) | 51.1 (15.0) | 53.0 | 21.3 |
| Suzhou Study | 3,061 | Chinese | Standard mercury sphygmomanometer, 2 | 54.2 (10.5) | 61.7 | 24.8 (3.6) | 134.2 (19.8) | 86.4 (10.2) | 70.5 (9.9) | 47.8 (14.3) | 47.2 | 27.5 |
AGEN=Asian Genetic Epidemiology Network; BP=Blood pressure; CAGE=Cardio-metabolic Genome Epidemiology; CLHNS=Cebu Longitudinal Health and Nutrition Survey; DBP=Diastolic blood pressure; GenSalt=Genetic Epidemiology Network of Salt-Sensitivity; GWAS=Genome-wide association study; HTN=Hypertension; JMPG=Japanese Millenium Genome Project; KARE=Korean Association Resource; MAP=Mean arterial pressure; N=sample size; NHAPC=Nutrition and Health of Aging Population in China; PP=Pulse pressure; SBP=Systolic blood pressure; SCES=Singapore Chinese Eyes Study; SD=Standard deviation; Vanderbilt=Vanderbilt Genome-Wide Association Studies; SiMES=Singapore Malay Eye Study; SMWHS=Shanghai Men’s and Shanghai Women’s Health Studies; SP2=Singapore Prospective Study.
Age in years;
Data are percentages;
Measurement in kilograms per square meters;
Measurement in mmHg;
MAP is calculated as DBP + (SBP–DBP)/3 in each study;
PP is calculated as SBP–DBP in each study
Hypertension is defined as SBP≥140 mmHg and DBP≥90 mmHg or taking antihypertension medication.